
As CGTs scale from clinical to commercial, Cencora's Krystal Haynes discusses the supply chain decisions that determine whether a launch succeeds.
Krystal Haynes is senior director, international 3PL business development, at Cencora.

As CGTs scale from clinical to commercial, Cencora's Krystal Haynes discusses the supply chain decisions that determine whether a launch succeeds.

Sponsored
Krystal Haynes, Senior Director of Business Development, ICS, at Cencora, outlines the challenges facing cell and gene therapy manufacturers as they attempt to move products from clinical development to commercial availability.